European Innovation Council

Onego Bio is a food-based biotechnology company that produces animal-free egg white protein through precision fermentation. Their ingredient, Bioalbumen, sets a new standard for sustainable protein with identical taste and nutrition, superior functional properties, and over 90% smaller environmental footprint compared to eggs from chickens. Onego’s highly productive and scalable technology caters to the needs of the food industry searching for stable, sustainable functional ingredients. As a game-changer in the field, the company was selected as the Winner of Fast Company’s 2023 World Changing Ideas awards and is a co-founder of two industry associations: Precision Fermentation Alliance and Food Fermentation Europe.

iOnctura is a biopharmaceutical company that develops novel therapeutics aimed at addressing immunosuppression within the tumor microenvironment, which can hinder effective cancer treatment. The company focuses on creating next-generation biomolecules to enhance existing immune checkpoint therapies, ultimately aiming to improve patient outcomes in cancer treatment. Through collaborations with Merck and Cancer Research Technology, iOnctura is advancing a pipeline of preclinical molecules designed to be used in combination with immuno-oncology therapies. With access to state-of-the-art drug discovery laboratories and a network of academic partners, iOnctura is strategically positioned to develop innovative combination therapies in cancer immunology, ensuring a focused approach to tackling the complexities of cancer and fibrosis.

Antabio is a private biopharmaceutical company based in Labege, France, focused on developing novel treatments for drug-resistant infections, particularly targeting critical priority pathogens. Founded in 2009, the company specializes in creating antibacterial resistance-breakers that can restore the efficacy of existing antibiotics. Its key innovation includes inhibitors of bacterial metalloenzymes, specifically Metallo ß-lactamases (MBLs), which are designed to be used in combination with carbapenems to address significant treatment gaps in drug-resistant nosocomial infections. Antabio aims to provide health professionals with effective medicinal products to combat life-threatening respiratory infections, including carbapenem-resistant pneumonia and chronic pulmonary diseases. The company has received recognition for its research efforts, including a Wellcome Trust Seeding Drug Discovery Award.

NEOGAP Therapeutics is a clinical-stage biopharmaceutical startup focused on immuno oncology. Their pharmaceutical product, personalized tumor trained lymphocytes, offers even one customized cell treatment that is meant to precisely target and destroy cancer in a tailored environment, with very minor side effects.

Cellbox Solutions is a young technology company that focuses on innovative logistic solutions for the global BioMed industry.

ARTHEx Biotech S.L. is a spin-off company of the University of Valencia that is developing antisense RNA treatments against genetic diseases. Our team has a strong background on drug discovery and microRNAs involvement in neuromuscular diseases. We are supported by world-renowned scientific and clinical advisors that will facilitate the successful development of our products.

Abbelight specializes in super-resolution microscopy and membrane imaging, focusing on single molecule localization microscopy to enhance biological research. The company integrates consumables, hardware, and software to deliver advanced scientific solutions, allowing researchers in biology, pharmacology, and environmental studies to utilize super-resolved fluorescence microscopy for improved observation of biological samples. Abbelight aims to democratize access to these sophisticated techniques by simplifying their application while maintaining high performance standards. To support scientists throughout the research process, Abbelight offers expertise in sample preparation and result analysis, providing a comprehensive approach that combines chemistry, computer science, and optical instruments.

Inobiostar focuses on research and experimental development services.

Smart Immune is a clinical-stage biotechnology company focused on developing innovative hematopoietic stem cell-based therapies aimed at improving the prognosis and quality of life for patients with serious diseases. The company's primary program utilizes T cell progenitors, known as ProTcells, which are designed to facilitate a rapid and safe immune recovery following transplantation. This therapy seeks to provide a polyclonal immune response, enhancing the body's ability to combat cancers and infections. Additionally, Smart Immune plans to complement its core offerings with advancements in targeted conditioning, gene therapy, and genome editing, thereby creating next-generation treatments for a range of inherited blood disorders and hematological malignancies.

Samplix is a biotechnology company based in Herlev, Denmark, focused on single-molecule sample preparation for DNA and RNA. It has developed the Xdrop™ technology, which utilizes a unique “water-oil-water” droplet system to create millions of reaction chambers for handling individual DNA molecules. This innovative approach allows for targeted enrichment of large DNA fragments and enables researchers to sequence specific genetic regions effectively. Samplix's technology addresses the limitations of existing multi-molecule preparation methods, providing enhanced precision and sensitivity while simplifying the sample preparation process. Its solutions empower scientists to make informed research decisions, particularly in applications related to virus integration and CRISPR editing.

Samplix is a biotechnology company based in Herlev, Denmark, focused on single-molecule sample preparation for DNA and RNA. It has developed the Xdrop™ technology, which utilizes a unique “water-oil-water” droplet system to create millions of reaction chambers for handling individual DNA molecules. This innovative approach allows for targeted enrichment of large DNA fragments and enables researchers to sequence specific genetic regions effectively. Samplix's technology addresses the limitations of existing multi-molecule preparation methods, providing enhanced precision and sensitivity while simplifying the sample preparation process. Its solutions empower scientists to make informed research decisions, particularly in applications related to virus integration and CRISPR editing.

Smart Immune is a clinical-stage biotechnology company focused on developing innovative hematopoietic stem cell-based therapies aimed at improving the prognosis and quality of life for patients with serious diseases. The company's primary program utilizes T cell progenitors, known as ProTcells, which are designed to facilitate a rapid and safe immune recovery following transplantation. This therapy seeks to provide a polyclonal immune response, enhancing the body's ability to combat cancers and infections. Additionally, Smart Immune plans to complement its core offerings with advancements in targeted conditioning, gene therapy, and genome editing, thereby creating next-generation treatments for a range of inherited blood disorders and hematological malignancies.

TILT Biotherapeutics Ltd is a preclinical stage biotechnology company based in Helsinki, Finland, specializing in the development of genetically modified oncolytic viruses aimed at enhancing cancer treatments. The company's patented technology focuses on using these viruses to improve tumor T-cell therapies, including tumor-infiltrating lymphocyte (TIL) and chimeric antigen receptor (CAR-T) therapies, as well as checkpoint inhibitors. TILT Biotherapeutics is recognized as a leader in the global market for integrating oncolytic viruses with cancer immunotherapy. Their product pipeline includes TILT-123, TILT-234, and TILT-321, which are designed to modify the tumor microenvironment and counteract its suppression of immune responses. The innovative approach has the potential to replicate the successes seen in CAR-T therapy for solid tumors, similar to those achieved in hematological cancers.

TILT Biotherapeutics Ltd is a preclinical stage biotechnology company based in Helsinki, Finland, specializing in the development of genetically modified oncolytic viruses aimed at enhancing cancer treatments. The company's patented technology focuses on using these viruses to improve tumor T-cell therapies, including tumor-infiltrating lymphocyte (TIL) and chimeric antigen receptor (CAR-T) therapies, as well as checkpoint inhibitors. TILT Biotherapeutics is recognized as a leader in the global market for integrating oncolytic viruses with cancer immunotherapy. Their product pipeline includes TILT-123, TILT-234, and TILT-321, which are designed to modify the tumor microenvironment and counteract its suppression of immune responses. The innovative approach has the potential to replicate the successes seen in CAR-T therapy for solid tumors, similar to those achieved in hematological cancers.

Iris.ai offers an AI-powered science assistant designed to enhance the efficiency of research and development departments by facilitating the navigation of scientific literature. Its primary product, RSpace, features advanced search capabilities, smart filters, reading list analysis, auto-generated summaries, and automated data extraction, enabling users to systematically organize information. By leveraging natural language processing algorithms, Iris.ai addresses the challenges of factuality tracking in AI, providing tools that enhance the accuracy and reliability of scientific research. This platform is aimed at both corporate R&D teams and academic researchers, allowing them to uncover new scientific insights that go beyond traditional human capabilities.

Iris.ai offers an AI-powered science assistant designed to enhance the efficiency of research and development departments by facilitating the navigation of scientific literature. Its primary product, RSpace, features advanced search capabilities, smart filters, reading list analysis, auto-generated summaries, and automated data extraction, enabling users to systematically organize information. By leveraging natural language processing algorithms, Iris.ai addresses the challenges of factuality tracking in AI, providing tools that enhance the accuracy and reliability of scientific research. This platform is aimed at both corporate R&D teams and academic researchers, allowing them to uncover new scientific insights that go beyond traditional human capabilities.

iOnctura is a biopharmaceutical company that develops novel therapeutics aimed at addressing immunosuppression within the tumor microenvironment, which can hinder effective cancer treatment. The company focuses on creating next-generation biomolecules to enhance existing immune checkpoint therapies, ultimately aiming to improve patient outcomes in cancer treatment. Through collaborations with Merck and Cancer Research Technology, iOnctura is advancing a pipeline of preclinical molecules designed to be used in combination with immuno-oncology therapies. With access to state-of-the-art drug discovery laboratories and a network of academic partners, iOnctura is strategically positioned to develop innovative combination therapies in cancer immunology, ensuring a focused approach to tackling the complexities of cancer and fibrosis.

iOnctura is a biopharmaceutical company that develops novel therapeutics aimed at addressing immunosuppression within the tumor microenvironment, which can hinder effective cancer treatment. The company focuses on creating next-generation biomolecules to enhance existing immune checkpoint therapies, ultimately aiming to improve patient outcomes in cancer treatment. Through collaborations with Merck and Cancer Research Technology, iOnctura is advancing a pipeline of preclinical molecules designed to be used in combination with immuno-oncology therapies. With access to state-of-the-art drug discovery laboratories and a network of academic partners, iOnctura is strategically positioned to develop innovative combination therapies in cancer immunology, ensuring a focused approach to tackling the complexities of cancer and fibrosis.

Elicit Plant is an agro-biotech company focused on enhancing the resilience of crops to water stress and developing phytosterol-based solutions. By leveraging proprietary technology, Elicit Plant aims to address the challenges posed by climate change on agriculture. The company’s products are designed to improve plant stress resistance and activate natural defenses, which has been validated through extensive field trials across three continents. These trials demonstrate that Elicit Plant's biosolutions provide farmers with consistent and significant returns on investment, positioning the company as a leader in the ecological transition within the agricultural sector.

Herantis Pharma is a biotechnology company focused on addressing unmet clinical needs through the development of disease-modifying therapies for Parkinson's disease. The company's primary development program centers on HER-096, a peptidomimetic molecule engineered to preserve the biological activity of the neuroprotective CDNF protein. By targeting the underlying mechanisms of the disease, Herantis Pharma aims to provide innovative treatment options for patients suffering from Parkinson's disease.

Herantis Pharma is a biotechnology company focused on addressing unmet clinical needs through the development of disease-modifying therapies for Parkinson's disease. The company's primary development program centers on HER-096, a peptidomimetic molecule engineered to preserve the biological activity of the neuroprotective CDNF protein. By targeting the underlying mechanisms of the disease, Herantis Pharma aims to provide innovative treatment options for patients suffering from Parkinson's disease.

Xenikos is focused on developing innovative immunotherapy treatments aimed at addressing serious immune diseases and complications arising from transplants. The company specializes in anti-T-cell antibodies that can effectively reset the immune system. This therapeutic approach involves injecting a specific agent that targets and eliminates adult T cells, particularly those that are activated, thereby enhancing treatment outcomes for patients. By leveraging this unique mechanism, Xenikos seeks to restore health and improve the quality of life for individuals facing significant immune-related challenges.

Vésale Pharma work with internationally renowned research organizations.They offer innovative healthcare solutions adapted to everyone.

Hemispherian is a biotechnology company focused on developing innovative treatments for various types of cancer, particularly aggressive forms such as glioblastoma multiforme. The firm specializes in personalized cancer therapies and is working on a new class of small-molecule drugs designed to address significant unmet medical needs in oncology. By formulating these advanced treatments, Hemispherian aims to provide physicians with access to novel therapeutic options that can improve patient outcomes in the fight against cancer.

Celeris Therapeutics is an AI-driven drug discovery company focused on developing proximity-inducing compounds (PICs), particularly PIC degraders, to address diseases with significant unmet medical needs, including Parkinson's disease and various cancers. The company utilizes its proprietary Celeris One platform, which employs structure-based geometric deep learning to enhance the design and development of degraders. This platform aids in the prioritization of specific E3 ligases, the design of linkers, and the selection of the most promising compounds for synthesis. Additionally, Celeris Therapeutics operates an automated laboratory that rapidly generates experimental data for further optimization. The company collaborates with pharmaceutical and biotech firms to co-develop small-molecule degrader therapies across various therapeutic areas while also building its own drug pipeline. Celeris Therapeutics maintains offices in Menlo Park, California, and Graz, Austria.

Hemispherian is a biotechnology company focused on developing innovative treatments for various types of cancer, particularly aggressive forms such as glioblastoma multiforme. The firm specializes in personalized cancer therapies and is working on a new class of small-molecule drugs designed to address significant unmet medical needs in oncology. By formulating these advanced treatments, Hemispherian aims to provide physicians with access to novel therapeutic options that can improve patient outcomes in the fight against cancer.

Immunethep is a biotechnology company focused on developing innovative therapies for immune system-related diseases. Originating as a spin-off from the University of Porto, the company leverages proprietary technology to address significant unmet medical needs. Immunethep has identified a novel mechanism by which various pathogenic bacteria suppress the host immune response. By targeting this mechanism, the company aims to create broad-spectrum anti-bacterial immunotherapies. Among its initiatives, Immunethep is working on neonatal vaccines designed to protect infants from bacterial infections before birth, thereby enhancing their immunity and preventing multi-bacterial infections. Through these advancements, Immunethep strives to improve patient outcomes and contribute to the field of advanced healthcare.

Immunethep is a biotechnology company focused on developing innovative therapies for immune system-related diseases. Originating as a spin-off from the University of Porto, the company leverages proprietary technology to address significant unmet medical needs. Immunethep has identified a novel mechanism by which various pathogenic bacteria suppress the host immune response. By targeting this mechanism, the company aims to create broad-spectrum anti-bacterial immunotherapies. Among its initiatives, Immunethep is working on neonatal vaccines designed to protect infants from bacterial infections before birth, thereby enhancing their immunity and preventing multi-bacterial infections. Through these advancements, Immunethep strives to improve patient outcomes and contribute to the field of advanced healthcare.

Actome focuses on developing emulsion coupling technology for life science research and personalized medicine.

AcouSort is a Swedish company specializing in the development and sale of laboratory products and integrated solutions that utilize ultrasound technology for the separation, washing, and enrichment of biological samples. Its offerings cater to researchers and life science companies, focusing on the automated preparation of samples such as blood cells, bacteria, and extracellular vesicles. The technology is rooted in acoustofluidics research from the esteemed group led by Professor Thomas Laurell at Lund University's Department of Biomedical Engineering. Key products include AcouTrap, AcouWash, and AcouPlasma, which facilitate efficient handling of microscopic particles in microfluidic channels for research and diagnostic applications.

Ovagen is a biotechnology company specializing in the large-scale production of germ-free chicken eggs and birds, primarily for the pharmaceutical industry. The company's innovative process utilizes a transgenic chicken platform to produce recombinant proteins to Good Manufacturing Practice (GMP) standards. This technology provides pharmaceutical companies with a biosecure and flexible biomanufacturing solution for developing vaccines and therapeutic proteins. In addition to its core offerings, Ovagen also provides Contract Research Services and has expertise in specific poultry and rodent research technologies, as well as in SPF poultry and rodent housing and husbandry.

Metafora Biosystems is a biotechnology company focused on developing receptor binding domains (RBDs), which are innovative ligands targeting nutrient transporters. Their technology enables the detection of subtle quantitative changes in cell physiology, reflecting metabolic variations caused by factors such as drugs, genetic mutations, cell culture conditions, and diseases. This capability positions Metafora's tools as competitive assets in various segments of the biomarker market, offering unique insights into cellular responses and enhancing understanding of metabolic processes.

Antabio is a private biopharmaceutical company based in Labege, France, focused on developing novel treatments for drug-resistant infections, particularly targeting critical priority pathogens. Founded in 2009, the company specializes in creating antibacterial resistance-breakers that can restore the efficacy of existing antibiotics. Its key innovation includes inhibitors of bacterial metalloenzymes, specifically Metallo ß-lactamases (MBLs), which are designed to be used in combination with carbapenems to address significant treatment gaps in drug-resistant nosocomial infections. Antabio aims to provide health professionals with effective medicinal products to combat life-threatening respiratory infections, including carbapenem-resistant pneumonia and chronic pulmonary diseases. The company has received recognition for its research efforts, including a Wellcome Trust Seeding Drug Discovery Award.

Antabio is a private biopharmaceutical company based in Labege, France, focused on developing novel treatments for drug-resistant infections, particularly targeting critical priority pathogens. Founded in 2009, the company specializes in creating antibacterial resistance-breakers that can restore the efficacy of existing antibiotics. Its key innovation includes inhibitors of bacterial metalloenzymes, specifically Metallo ß-lactamases (MBLs), which are designed to be used in combination with carbapenems to address significant treatment gaps in drug-resistant nosocomial infections. Antabio aims to provide health professionals with effective medicinal products to combat life-threatening respiratory infections, including carbapenem-resistant pneumonia and chronic pulmonary diseases. The company has received recognition for its research efforts, including a Wellcome Trust Seeding Drug Discovery Award.

Metafora Biosystems is a biotechnology company focused on developing receptor binding domains (RBDs), which are innovative ligands targeting nutrient transporters. Their technology enables the detection of subtle quantitative changes in cell physiology, reflecting metabolic variations caused by factors such as drugs, genetic mutations, cell culture conditions, and diseases. This capability positions Metafora's tools as competitive assets in various segments of the biomarker market, offering unique insights into cellular responses and enhancing understanding of metabolic processes.

Celeris Therapeutics is an AI-driven drug discovery company focused on developing proximity-inducing compounds (PICs), particularly PIC degraders, to address diseases with significant unmet medical needs, including Parkinson's disease and various cancers. The company utilizes its proprietary Celeris One platform, which employs structure-based geometric deep learning to enhance the design and development of degraders. This platform aids in the prioritization of specific E3 ligases, the design of linkers, and the selection of the most promising compounds for synthesis. Additionally, Celeris Therapeutics operates an automated laboratory that rapidly generates experimental data for further optimization. The company collaborates with pharmaceutical and biotech firms to co-develop small-molecule degrader therapies across various therapeutic areas while also building its own drug pipeline. Celeris Therapeutics maintains offices in Menlo Park, California, and Graz, Austria.

Qubit Pharmaceuticals is a Paris-based company founded in 2020 that specializes in drug discovery technology. Established through collaboration among notable institutions such as CNAM, CNRS, the University of Texas at Austin, Sorbonne University, and Washington University, it draws on over 20 years of research and development recognized by prestigious awards. The company has developed a drug discovery simulation platform that aims to reduce both the cost and duration of preclinical drug development. Utilizing proprietary force field models and molecular dynamics calculations, the platform conducts virtual screening and visualization to identify promising drug candidates. This innovative approach leverages quantum physics to support biopharmaceutical companies in accelerating their research and development efforts.

Elicera Therapeutics is a clinical stage immuno-oncology company developing cell and gene therapies for immune-based cancer treatments.

Core Biogenesis is a biotechnology company based in Paris, France, established in 2020. It specializes in next-generation recombinant protein production technologies, utilizing proprietary gene editing and plant biotechnology to significantly lower the costs associated with producing growth factors. These growth factors are crucial for applications in the clean meat and cell therapy industries. The company has developed an ultra-scalable bioproduction platform that leverages plants as biofactories, enabling efficient mass production and targeted extraction of valuable bioproducts. This innovative approach not only accelerates production but also enhances the ability to regulate cell growth and increases yields, making it a valuable partner for clients in the healthcare sector.

BrainEver focuses on developing innovative therapeutics for neurodegenerative disorders, rooted in the research of Alain Prochiantz and colleagues on brain development and physiology. The company explores the potential of homeoproteins, which are known to regulate neuronal functions throughout life, to enhance the physiological resistance and activity of surviving neurons in patients. This approach aims to improve clinical symptoms in conditions such as Parkinson's disease and amyotrophic lateral sclerosis (ALS). The company is advancing its lead candidate, Engrailed 1 (BREN01), while also working on a pipeline of additional drug candidates targeting other neurodegenerative diseases, including Huntington's disease and optic neuropathies. By developing these novel therapeutics, BrainEver aims to provide effective treatment options for healthcare practitioners and patients affected by these challenging conditions.

Scipio Bioscience is a biotechnology company based in Paris, France, founded in 2017. The company specializes in manufacturing benchtop kits that provide a sample preparation solution for single-cell studies. These kits are designed for use in sequencing applications within both clinical and basic research, particularly in the field of transcriptomics. Scipio Bioscience's innovative products enable research laboratories to perform single-cell barcoding in a test tube format, facilitating advanced analysis and research in the life sciences.

Scipio Bioscience is a biotechnology company based in Paris, France, founded in 2017. The company specializes in manufacturing benchtop kits that provide a sample preparation solution for single-cell studies. These kits are designed for use in sequencing applications within both clinical and basic research, particularly in the field of transcriptomics. Scipio Bioscience's innovative products enable research laboratories to perform single-cell barcoding in a test tube format, facilitating advanced analysis and research in the life sciences.

Camino Science is a biotechnology company based in Bialystok, Poland, that specializes in molecular biology research. The company develops innovative biotech tools and utilizes artificial intelligence to enhance scientific inquiry and understanding. By integrating advanced technology with biological research, Camino Science aims to contribute to advancements in the field and support the scientific community in its endeavors.

Core Biogenesis is a biotechnology company based in Paris, France, established in 2020. It specializes in next-generation recombinant protein production technologies, utilizing proprietary gene editing and plant biotechnology to significantly lower the costs associated with producing growth factors. These growth factors are crucial for applications in the clean meat and cell therapy industries. The company has developed an ultra-scalable bioproduction platform that leverages plants as biofactories, enabling efficient mass production and targeted extraction of valuable bioproducts. This innovative approach not only accelerates production but also enhances the ability to regulate cell growth and increases yields, making it a valuable partner for clients in the healthcare sector.

TILT Biotherapeutics Ltd is a preclinical stage biotechnology company based in Helsinki, Finland, specializing in the development of genetically modified oncolytic viruses aimed at enhancing cancer treatments. The company's patented technology focuses on using these viruses to improve tumor T-cell therapies, including tumor-infiltrating lymphocyte (TIL) and chimeric antigen receptor (CAR-T) therapies, as well as checkpoint inhibitors. TILT Biotherapeutics is recognized as a leader in the global market for integrating oncolytic viruses with cancer immunotherapy. Their product pipeline includes TILT-123, TILT-234, and TILT-321, which are designed to modify the tumor microenvironment and counteract its suppression of immune responses. The innovative approach has the potential to replicate the successes seen in CAR-T therapy for solid tumors, similar to those achieved in hematological cancers.

Betalin Therapeutics is a privately-held company. We develop a cell therapy solution for insulin-dependent diabetes, an Engineered Micro-Pancreas (EMP). The EMP is a combination of harvested pancreatic islets (also known as Islets of Langerhans) and a proprietary biological micro-environment for supporting the harvested cells. After promising in-vitro results and preliminary in-vivo results, Betalin Therapeutics is currently putting efforts to further optimize the therapy in animal models, complete submission of the Investigational New Drug (IND) application to the FDA, and proceed to clinical trials.

VBL Therapeutics is a clinical-stage biotechnology company focused on developing innovative treatments for cancer and immune-inflammatory diseases. The company’s clinical pipeline features two proprietary platform technologies that utilize the body’s natural biological and genetic mechanisms. Their lead product candidate, VB-111, is a gene-based biologic aimed at treating solid tumors, particularly recurrent glioblastoma, an aggressive brain cancer. In addition to its oncology efforts, VBL is also working on therapies for anti-inflammatory conditions through its Lecinoxoid platform technology. The company is dedicated to advancing first-in-class treatments that address significant unmet medical needs.

VBL Therapeutics is a clinical-stage biotechnology company focused on developing innovative treatments for cancer and immune-inflammatory diseases. The company’s clinical pipeline features two proprietary platform technologies that utilize the body’s natural biological and genetic mechanisms. Their lead product candidate, VB-111, is a gene-based biologic aimed at treating solid tumors, particularly recurrent glioblastoma, an aggressive brain cancer. In addition to its oncology efforts, VBL is also working on therapies for anti-inflammatory conditions through its Lecinoxoid platform technology. The company is dedicated to advancing first-in-class treatments that address significant unmet medical needs.

EVerZom is a nanomedicine biotech company based in Paris, France, specializing in the large-scale manufacturing of extracellular vesicles. Founded in 2019, the company has developed a unique, GMP-compliant bioproduction platform aimed at pharmaceutical companies. This platform enables the production of various types of extracellular vesicles, including exosomes, microvesicles, and apoptotic bodies, which are essential for intercellular communication. EVerZom's products possess protective and reparative properties, making them valuable therapeutic tools in regenerative medicine and drug delivery. The company's technology is designed to assist healthcare professionals in addressing organ failure and restoring function and homeostasis.

Computomics GmbH is a bioinformatics company based in Tübingen, Germany, specializing in molecular data analysis for crop biotechnology and agricultural research. Founded in 2012, the company offers a range of services, including the analysis of large, polyploid plant genomes, transcriptome studies, differential gene expression, and functional genome annotation. It also provides reference-free genotyping, DNA methylation analysis, and metagenomic analysis. By applying advanced machine learning models to biological data, Computomics helps researchers accelerate genetic gains and make informed decisions in over 190 projects. The company's goal is to support sustainable agricultural development, enabling clients in agriculture, biotechnology, microbiome research, and metabolomics to derive actionable insights from their genomic data.

Next Generation Sensors is a biotech business that creates mass spectrometers for commercial uses in the life sciences. Finding rapid, accurate screening information for potential health, security, and environmental hazards relies on. By bringing the lab to the sample with portable, sensitive, accurate, and user-friendly technology for quick detection of dangerous compounds in our food, bodies, and environment, offers answers for a safer future.

Sequentia Biotech was founded in 2013 by Walter Sanseverino (CEO) and Riccardo Aiese Cigliano (CSO), two young researchers with a real passion for genetics and omics sciences, and is based at the UAB Research Park. Sequentia is a bioinformatics company that offers services and tools that transform genomic data into knowledge in academic research, plant and animal breeding and biomedicine. In just four years, Sequentia has achieved a large highly diversified portfolio of clients and partners, consisting of over 30 public and private research centers, companies and hospitals. The company is taking part in more than 160 R & D public and private projects, and it has two open source biodata banks; and an award-winning R&D line, Tricopharming, which was established in 2014. Cofounders Walter Sanseverino and Riccardo Aiese have published more than 40 scientific articles in high impact journals such as Nature Genetics, Scientific Report or DNA Research.

adivo is a veterinary biotechnology company developing therapeutic antibodies for pets. The focus is on the treatment of serious diseases in dogs with the potential to offer therapies for other species as well. The antibody selection is based on a new, fully synthetic, dog-specific drug library that can be used to isolate antibodies with optimal properties using phage display technology. adivo is a spin-off of MorphoSys AG. Many years of expertise in the development of human therapeutic antibodies transfer the adivo team into veterinary medicine.

Sequentia Biotech was founded in 2013 by Walter Sanseverino (CEO) and Riccardo Aiese Cigliano (CSO), two young researchers with a real passion for genetics and omics sciences, and is based at the UAB Research Park. Sequentia is a bioinformatics company that offers services and tools that transform genomic data into knowledge in academic research, plant and animal breeding and biomedicine. In just four years, Sequentia has achieved a large highly diversified portfolio of clients and partners, consisting of over 30 public and private research centers, companies and hospitals. The company is taking part in more than 160 R & D public and private projects, and it has two open source biodata banks; and an award-winning R&D line, Tricopharming, which was established in 2014. Cofounders Walter Sanseverino and Riccardo Aiese have published more than 40 scientific articles in high impact journals such as Nature Genetics, Scientific Report or DNA Research.

LiMM Therapeutics is a biopharmaceutical company focused on developing therapeutic agents aimed at addressing inflammatory, infectious, and metabolic diseases. The company leverages the molecular interactions between neuronal and innate lymphoid cells to create innovative products that aim to preserve health and improve patient outcomes. By bridging discoveries in neural sensing and immunology, LiMM Therapeutics seeks to unlock new therapeutic solutions that enhance immune regulation and combat infections. Through its research and development efforts, the company aspires to provide healthcare professionals with a pipeline of novel treatments to better manage various health conditions.

Over the past couple of decades, the exponential progress of sequencing technologies has allowed an increasing number of cancer patients to benefit from precision oncology. However, the aggregation, analysis, and visualization of the massive amounts of genomic data remain a major challenge for precision oncology expansion. The Epigene Labs technology platform enables cancer drug hunters to seamlessly leverage advanced artificial intelligence in transforming genomic data into actionable insights for designing precision oncology approaches. With R&D in Paris and business development in Boston, Epigene Labs operates in the setting of value-based partnerships with world leading cancer centers and high-profile biotechs.

adivo is a veterinary biotechnology company developing therapeutic antibodies for pets. The focus is on the treatment of serious diseases in dogs with the potential to offer therapies for other species as well. The antibody selection is based on a new, fully synthetic, dog-specific drug library that can be used to isolate antibodies with optimal properties using phage display technology. adivo is a spin-off of MorphoSys AG. Many years of expertise in the development of human therapeutic antibodies transfer the adivo team into veterinary medicine.

RemedyBio is an immunology-focused discovery and development company located in Dublin, Ireland. The company specializes in creating therapeutics aimed at enhancing immunotherapies for complex diseases. RemedyBio has developed innovative technology that accelerates and scales single-cell analysis, which plays a crucial role in advancing treatments in areas such as immuno-oncology, autoimmune diseases, and infectious diseases. By leveraging this technology, RemedyBio seeks to provide the healthcare industry with more effective therapeutic and diagnostic solutions.

Qubit Pharmaceuticals is a Paris-based company founded in 2020 that specializes in drug discovery technology. Established through collaboration among notable institutions such as CNAM, CNRS, the University of Texas at Austin, Sorbonne University, and Washington University, it draws on over 20 years of research and development recognized by prestigious awards. The company has developed a drug discovery simulation platform that aims to reduce both the cost and duration of preclinical drug development. Utilizing proprietary force field models and molecular dynamics calculations, the platform conducts virtual screening and visualization to identify promising drug candidates. This innovative approach leverages quantum physics to support biopharmaceutical companies in accelerating their research and development efforts.

DELMIC specializes in correlative light and electron microscopy technology, focusing on applications in life and materials science research. The company offers a range of services, including cathodoluminescence, automated cryo-electron tomography workflows, and efficient electron microscopy solutions. These services are designed to enhance research capabilities by providing reliable and high-throughput methodologies, enabling researchers and organizations to gain insights more quickly and effectively. Through its innovative tools and integrated microscopy approaches, DELMIC aims to facilitate advancements in scientific research.

Synovance is focused on advancing the bio-based economy through the development of plant-derived resources for a variety of applications, including fuels, chemicals, materials, food, and feed. The company specializes in producing bio-based textile dyes and employs engineered organisms capable of efficiently converting biomass. By developing customized strains and assembling tailored secondary genomes, Synovance enables manufacturing industries to meet specific functional requirements across diverse applications. This innovative approach positions Synovance as a leader in sustainable practices, promoting environmentally responsible solutions for various sectors, including the textile industry.

Synovance is focused on advancing the bio-based economy through the development of plant-derived resources for a variety of applications, including fuels, chemicals, materials, food, and feed. The company specializes in producing bio-based textile dyes and employs engineered organisms capable of efficiently converting biomass. By developing customized strains and assembling tailored secondary genomes, Synovance enables manufacturing industries to meet specific functional requirements across diverse applications. This innovative approach positions Synovance as a leader in sustainable practices, promoting environmentally responsible solutions for various sectors, including the textile industry.

Hoba Therapeutics is focused on developing innovative biopharmaceuticals aimed at treating neuropathic pain and central nervous system disorders. The company is advancing a novel therapeutic protein designed to target specific cells, providing medical practitioners with effective, safe, and disease-modifying treatment options. Hoba Therapeutics aims to offer relief and prevention for chronic pain and hearing loss, addressing significant medical needs for patients suffering from these conditions.

Deep Branch Biotechnology Ltd., founded in 2018 and based in Nottingham, UK, specializes in carbon recycling services aimed at creating sustainable ingredients for food and feed. By utilizing clean and renewable carbon and energy sources, the company employs a proprietary gas fermentation platform that leverages sustainable feedstocks to produce bio-based products with a significantly reduced carbon footprint. Deep Branch focuses on customer-driven research and development, enabling it to swiftly deliver innovative solutions to meet the growing demand for sustainable food systems. The company collaborates with local suppliers of strategic raw materials, fostering local economies while ensuring a reliable input supply. With a clear roadmap for scaling its operations, Deep Branch has formed strong partnerships across the value chain and has integrated effectively with carbon dioxide suppliers to optimize the deployment of its technology. By producing ingredients that require no arable land and minimal water, Deep Branch is addressing climate change and biodiversity loss, contributing to a more sustainable future without compromising on nutritional quality.

LiMM Therapeutics is a biopharmaceutical company focused on developing therapeutic agents aimed at addressing inflammatory, infectious, and metabolic diseases. The company leverages the molecular interactions between neuronal and innate lymphoid cells to create innovative products that aim to preserve health and improve patient outcomes. By bridging discoveries in neural sensing and immunology, LiMM Therapeutics seeks to unlock new therapeutic solutions that enhance immune regulation and combat infections. Through its research and development efforts, the company aspires to provide healthcare professionals with a pipeline of novel treatments to better manage various health conditions.

SiriusXT Limited, based in Dublin, Ireland, specializes in the development and manufacturing of a soft x-ray microscope known as the SXT system. Founded in 2015, the company primarily serves researchers in disease research and drug discovery. The microscope employs a vacuum-based laser-produced plasma light source, enabling high-resolution imaging of the 3D internal structure of cells in their native, fully hydrated state. This technology is akin to a CT scan for cells, allowing for detailed visualization without the need for stains or contrast agents. The SXT system is particularly beneficial for disease researchers, pharmaceutical companies, and biotechnologists, as it facilitates the understanding of disease pathways, protein-drug interactions, and bio-engineering processes. As the first high-throughput, bench-top soft x-ray microscope, SiriusXT's system can produce full cell 3D tomographs in a matter of minutes, significantly advancing imaging capabilities in scientific research.

Ability Pharmaceuticals is a drug discovery and development company based in Barcelona, Spain. It develops human therapeutics targeting cell membranes to treat cancer and other indications with unmet medical needs. Ability Pharmaceuticals is focused on developing new drugs for the treatment of lung cancer and pancreatic cancer. The company develops Lipid Analogue Therapeutics, a new drug class that modifies the composition of the cell membrane and displays a capacity to influence the local organization of lipid structures in the cell membrane, inducing the formation of non-lamellar phase structures. Its development pipeline includes ABTL0812 product in preclinical development; and ABTL1014, a drug candidate in preclinical characterization.

SOMAprobes focuses on the development and commercialization of innovative diagnostic solutions that leverage the biology of nucleases. The company specializes in in vitro diagnostic tests aimed at identifying diseases that are often challenging to diagnose using traditional methods. Among its offerings are activatable contrast agents designed for MRI detection of bacterial pathogens, particularly at the onset of infectious diseases such as cancer, bone infections, and prosthetic joint infections. These advancements provide healthcare professionals with essential tools for rapid decision-making, improving patient outcomes through timely and accurate diagnosis.

Betalin Therapeutics is a privately-held company. We develop a cell therapy solution for insulin-dependent diabetes, an Engineered Micro-Pancreas (EMP). The EMP is a combination of harvested pancreatic islets (also known as Islets of Langerhans) and a proprietary biological micro-environment for supporting the harvested cells. After promising in-vitro results and preliminary in-vivo results, Betalin Therapeutics is currently putting efforts to further optimize the therapy in animal models, complete submission of the Investigational New Drug (IND) application to the FDA, and proceed to clinical trials.

SiriusXT Limited, based in Dublin, Ireland, specializes in the development and manufacturing of a soft x-ray microscope known as the SXT system. Founded in 2015, the company primarily serves researchers in disease research and drug discovery. The microscope employs a vacuum-based laser-produced plasma light source, enabling high-resolution imaging of the 3D internal structure of cells in their native, fully hydrated state. This technology is akin to a CT scan for cells, allowing for detailed visualization without the need for stains or contrast agents. The SXT system is particularly beneficial for disease researchers, pharmaceutical companies, and biotechnologists, as it facilitates the understanding of disease pathways, protein-drug interactions, and bio-engineering processes. As the first high-throughput, bench-top soft x-ray microscope, SiriusXT's system can produce full cell 3D tomographs in a matter of minutes, significantly advancing imaging capabilities in scientific research.

SOMAprobes focuses on the development and commercialization of innovative diagnostic solutions that leverage the biology of nucleases. The company specializes in in vitro diagnostic tests aimed at identifying diseases that are often challenging to diagnose using traditional methods. Among its offerings are activatable contrast agents designed for MRI detection of bacterial pathogens, particularly at the onset of infectious diseases such as cancer, bone infections, and prosthetic joint infections. These advancements provide healthcare professionals with essential tools for rapid decision-making, improving patient outcomes through timely and accurate diagnosis.

Betalin Therapeutics is a privately-held company. We develop a cell therapy solution for insulin-dependent diabetes, an Engineered Micro-Pancreas (EMP). The EMP is a combination of harvested pancreatic islets (also known as Islets of Langerhans) and a proprietary biological micro-environment for supporting the harvested cells. After promising in-vitro results and preliminary in-vivo results, Betalin Therapeutics is currently putting efforts to further optimize the therapy in animal models, complete submission of the Investigational New Drug (IND) application to the FDA, and proceed to clinical trials.

Biome Makers is a biotech company born in Silicon Valley specialized in the identification and understanding of the microbiome. They use DNA Sequencing technologies and proprietary Intelligent Computing systems to ease detailed information and recommendations that allow customers improve their agricultural production and the quality of their products.

Ability Pharmaceuticals is a drug discovery and development company based in Barcelona, Spain. It develops human therapeutics targeting cell membranes to treat cancer and other indications with unmet medical needs. Ability Pharmaceuticals is focused on developing new drugs for the treatment of lung cancer and pancreatic cancer. The company develops Lipid Analogue Therapeutics, a new drug class that modifies the composition of the cell membrane and displays a capacity to influence the local organization of lipid structures in the cell membrane, inducing the formation of non-lamellar phase structures. Its development pipeline includes ABTL0812 product in preclinical development; and ABTL1014, a drug candidate in preclinical characterization.

MeMed Diagnostics Ltd. is a personalized diagnostics company founded in 2009 and based in Tirat Carmel, Israel. The company develops innovative diagnostic solutions aimed at improving patient care and reducing healthcare costs, particularly through the prevention of antibiotic misuse. MeMed's flagship products include MeMed BV, a test that differentiates between bacterial and viral infections, and the ImmunoDx platform, which utilizes proprietary biomarkers and algorithms to analyze the immune system's responses to pathogens. This technology addresses significant challenges in infectious disease diagnostics, providing rapid and actionable insights that enable healthcare providers to make informed decisions regarding antibiotic treatments. By accurately identifying infection sources, MeMed aims to combat the inappropriate prescription of antibiotics, which contributes to the emergence of resistant bacterial strains and incurs substantial costs to healthcare systems worldwide.

Ophiomics S.A. is a clinical-stage biotech company based in Lisbon, Portugal, specializing in the development of diagnostic products and services for liver cancer. Established in 2015, Ophiomics focuses on integrating bioinformatics, artificial intelligence, and genomics to enhance diagnostic and prognostic capabilities in oncology. The company is ISO 13485 and ISO 9001 certified, ensuring adherence to high-quality standards in its operations. Its product pipeline encompasses various stages of development, including pre-clinical programs and those undergoing clinical validation. Ophiomics aims to improve early detection of liver cancer through biomarker-based diagnostic devices that combine molecular signatures with clinical parameters in predictive algorithms, ultimately assisting healthcare providers in treatment selection and clinical follow-up for better patient outcomes.

Brucella Green Vac SL is a research and product development company focused on combating animal diseases, specifically brucellosis, which is a widespread zoonotic disease affecting livestock. The company is dedicated to developing vaccines that provide a preventive measure against this chronic disease, thereby protecting both animal health and public safety. By implementing mass vaccination strategies for livestock, Brucella Green Vac aims to reduce the transmission of brucellosis to humans, ultimately contributing to healthier agricultural practices and safer food supply chains.

Ophiomics S.A. is a clinical-stage biotech company based in Lisbon, Portugal, specializing in the development of diagnostic products and services for liver cancer. Established in 2015, Ophiomics focuses on integrating bioinformatics, artificial intelligence, and genomics to enhance diagnostic and prognostic capabilities in oncology. The company is ISO 13485 and ISO 9001 certified, ensuring adherence to high-quality standards in its operations. Its product pipeline encompasses various stages of development, including pre-clinical programs and those undergoing clinical validation. Ophiomics aims to improve early detection of liver cancer through biomarker-based diagnostic devices that combine molecular signatures with clinical parameters in predictive algorithms, ultimately assisting healthcare providers in treatment selection and clinical follow-up for better patient outcomes.

S-Biomedic is a biotech company based in Beerse, Belgium, specializing in live probiotic cosmetics aimed at improving skin health. The company develops innovative products that target the skin microbiome, which consists of a diverse community of bacteria that can influence various skin conditions, including acne, eczema, rosacea, and signs of aging. Utilizing advanced modulation-based technology, S-Biomedic selects beneficial bacteria to create formulations that restore balance to the skin's microbiome. This approach not only addresses existing skin issues but also enhances overall skin health and beauty. By bridging advancements in microbiology and dermatology, S-Biomedic offers therapeutic solutions for both dermatological and cosmetic applications.

S-Biomedic is a biotech company based in Beerse, Belgium, specializing in live probiotic cosmetics aimed at improving skin health. The company develops innovative products that target the skin microbiome, which consists of a diverse community of bacteria that can influence various skin conditions, including acne, eczema, rosacea, and signs of aging. Utilizing advanced modulation-based technology, S-Biomedic selects beneficial bacteria to create formulations that restore balance to the skin's microbiome. This approach not only addresses existing skin issues but also enhances overall skin health and beauty. By bridging advancements in microbiology and dermatology, S-Biomedic offers therapeutic solutions for both dermatological and cosmetic applications.

Abbelight specializes in super-resolution microscopy and membrane imaging, focusing on single molecule localization microscopy to enhance biological research. The company integrates consumables, hardware, and software to deliver advanced scientific solutions, allowing researchers in biology, pharmacology, and environmental studies to utilize super-resolved fluorescence microscopy for improved observation of biological samples. Abbelight aims to democratize access to these sophisticated techniques by simplifying their application while maintaining high performance standards. To support scientists throughout the research process, Abbelight offers expertise in sample preparation and result analysis, providing a comprehensive approach that combines chemistry, computer science, and optical instruments.

Brucella Green Vac SL is a research and product development company focused on combating animal diseases, specifically brucellosis, which is a widespread zoonotic disease affecting livestock. The company is dedicated to developing vaccines that provide a preventive measure against this chronic disease, thereby protecting both animal health and public safety. By implementing mass vaccination strategies for livestock, Brucella Green Vac aims to reduce the transmission of brucellosis to humans, ultimately contributing to healthier agricultural practices and safer food supply chains.

SynHet specializes in the research and development of a diverse array of heterocycles for applications in agrochemicals, pharmaceuticals, and life sciences. The company manufactures organic and fine chemical products, leveraging an extensive global network of chemists to design and execute synthesis efficiently. By utilizing advanced technologies, including fully automated purification processes, SynHet is able to deliver compounds more rapidly and cost-effectively than traditional methods. This innovative approach enables the company to serve a wide range of global customers while enhancing its capabilities in scalable robotic synthesis.

Desentum is a research-oriented biopharmaceutical company specialized in developing novel types of allergy vaccines that are based on switching the immune system's response to allergens from hypersensitivity to tolerance. They have a unique approach for designing allergy vaccines. By studying the molecular mechanism of the hypersensitivity reaction, they have made discoveries that allow for improved design of vaccines against common types of allergies. Their goal is to provide long-term relief for patients suffering from allergic symptoms, as well as reduce the social and economic burden allergies cause to both individuals and society.

TILT Biotherapeutics Ltd is a preclinical stage biotechnology company based in Helsinki, Finland, specializing in the development of genetically modified oncolytic viruses aimed at enhancing cancer treatments. The company's patented technology focuses on using these viruses to improve tumor T-cell therapies, including tumor-infiltrating lymphocyte (TIL) and chimeric antigen receptor (CAR-T) therapies, as well as checkpoint inhibitors. TILT Biotherapeutics is recognized as a leader in the global market for integrating oncolytic viruses with cancer immunotherapy. Their product pipeline includes TILT-123, TILT-234, and TILT-321, which are designed to modify the tumor microenvironment and counteract its suppression of immune responses. The innovative approach has the potential to replicate the successes seen in CAR-T therapy for solid tumors, similar to those achieved in hematological cancers.

OncoHost is a clinical-stage biotechnology company developing personalized strategies to increase the success of cancer therapy. The company utilizing proprietary proteomic analysis, we aim to understand the patient's unique response to therapy and overcome one of the major obstacles in clinical oncology today's resistance to therapy. Based on robust scientific infrastructure and a strong IP position, OncoHost is launching an extensive clinical program with leading academic and clinical partners. OncoHost's platform analyzes proteomic changes in blood samples to monitor the dynamics of biological processes induced by the patient in response to given cancer therapy. Response Profiling also identifies potential drug targets, advancing the development of novel therapeutic strategies.OncoHost's profiling platform offers a new layer of information, enabling early identification of non-responsiveness to cancer treatments and the discovery of new targets to overcome treatment resistance. OncoHost was founded in 2017 and is headquartered in Binyamina, Israel.